Exposing the molecular heterogeneity of glycosylated biotherapeutics
Abstract The heterogeneity inherent in today’s biotherapeutics, especially as a result of heavy glycosylation, can affect a molecule’s safety and efficacy. Characterizing this heterogeneity is crucial for drug development and quality assessment, but existing methods are limited in their ability to a...
Main Authors: | Luis F. Schachner, Christopher Mullen, Wilson Phung, Joshua D. Hinkle, Michelle Irwin Beardsley, Tracy Bentley, Peter Day, Christina Tsai, Siddharth Sukumaran, Tomasz Baginski, Danielle DiCara, Nicholas J. Agard, Matthieu Masureel, Joshua Gober, Adel M. ElSohly, Rafael Melani, John E. P. Syka, Romain Huguet, Michael T. Marty, Wendy Sandoval |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2024-04-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-024-47693-8 |
Similar Items
-
Marijuana and the cannabinoids /
by: ElSohly, Mahmoud A.
Published: (2007) -
TILT Biotherapeutics
by: Akseli Hemminki
Published: (2017-05-01) -
Emerging protein biotherapeutics /
by: Grewal, Iqbal S.
Published: (2009) -
Integrated BioTherapeutics
by: M. Javad Aman
Published: (2018-06-01) -
Chromatographic and spectroscopic profiles of Cannabis of different origins/
by: 517013 Brenneisen, R., et al.